Oral Delivery of Chitosan‐Rosmarinic Acid Nanoparticles Ameliorates Mucosal Inflammation in a Mouse Model of Colitis
Advanced NanoBiomed Research · 2025-10 · 5 (10)
DOI: 10.1002/anbr.202500068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced NanoBiomed Research, online erschienen am 30.06.2025. Verfasst von Afia Tasnim Rahman und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic disorder characterized by intestinal barrier dysfunction, excessive immune activation, and oxidative stress. Current treatment options, such as 5‐aminosalicylic acid (5‐ASA), exhibit limited therapeutic efficacy due to poor bioavailability and inability to restore intestinal homeostasis. Herein, a novel nanomedicine that can be orally administered, low‐molecular‐weight chitosan‐conjugated rosmarinic acid nanoparticles (LMWC‐RANPs), designed to enhance IBD treatment through its mucoadhesive, antioxidant, and immunomodulatory properties, are introduced. LMWC‐RANPs exhibit strong mucoadhesion, leading to prolonged retention in the inflamed gastrointestinal tract and efficient ROS scavenging. In a DSS‐induced mouse model of colitis, LMWC‐RANPs significantly alleviate disease symptoms by reducing body weight loss, preserving colon length, and restoring intestinal barrier integrity. Additionally, LMWC‐RANPs effectively modulate the mucosal immune response by promoting macrophage polarization from pro‐inflammatory (M1) to anti‐inflammatory (M2) phenotypes and reducing Th17 cell populations while enhancing regulatory T cell (Treg) frequencies. Furthermore, oral administration of LMWC‐RANPs exhibits no observable systemic toxicity in healthy mice, as confirmed by hematological and histopathological analyses. Collectively, these findings demonstrate the potential of LMWC‐RANPs as a safe and effective therapeutic for inflammatory bowel disease, with broader implications for other gut‐associated inflammatory diseases.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Rahman, A. T., Kang, S., & Jon, S. (2025). Oral Delivery of Chitosan‐Rosmarinic Acid Nanoparticles Ameliorates Mucosal Inflammation in a Mouse Model of Colitis. Advanced NanoBiomed Research, 5(10). https://doi.org/10.1002/anbr.202500068
Vancouver
Rahman AT, Kang S, Jon S. Oral Delivery of Chitosan‐Rosmarinic Acid Nanoparticles Ameliorates Mucosal Inflammation in a Mouse Model of Colitis. Advanced NanoBiomed Research. 2025;5(10). doi:10.1002/anbr.202500068
BibTeX
@article{Rahman2025,
author = {Rahman, Afia Tasnim and Kang, Sungyeon and Jon, Sangyong},
title = {Oral Delivery of Chitosan‐Rosmarinic Acid Nanoparticles Ameliorates Mucosal Inflammation in a Mouse Model of Colitis},
journal = {Advanced NanoBiomed Research},
year = {2025},
volume = {5},
number = {10},
doi = {10.1002/anbr.202500068}
}
EUVIMED